
## Victor J Van Den Berg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9255089/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Variability in lipid measurements can have major impact on treatment during secondary prevention. European Journal of Preventive Cardiology, 2022, 28, e4-e5.	0.8	0
2	Depletion of Homeostatic Antibodies against Malondialdehyde-Modified Low-Density Lipoprotein Correlates with Adverse Events in Major Vascular Surgery. Antioxidants, 2022, 11, 271.	2.2	1
3	Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events. Biomarkers, 2022, 27, 264-269.	0.9	3
4	Temporal Evolution of Serum Concentrations of Highâ€Sensitivity Cardiac Troponin During 1 Year After Acute Coronary Syndrome Admission. Journal of the American Heart Association, 2021, 10, e017393.	1.6	6
5	IGF-1 is not related to long-term outcome in hyperglycemic acute coronary syndrome patients. Diabetes and Vascular Disease Research, 2021, 18, 147916412110474.	0.9	1
6	Evolution of renal function and predictive value of serial renal assessments among patients with acute coronary syndrome: BIOMArCS study. International Journal of Cardiology, 2020, 299, 12-19.	0.8	3
7	Longitudinal patterns of N-terminal pro B-type natriuretic peptide, troponin T, and C-reactive protein in relation to the dynamics of echocardiographic parameters in heart failure patients. European Heart Journal Cardiovascular Imaging, 2020, 21, 1005-1012.	0.5	7
8	Health-related quality of life and cardiac rehabilitation: Does body mass index matter?. Journal of Rehabilitation Medicine, 2020, 52, jrm00083.	0.8	2
9	High-frequency metabolite profiling and the incidence of recurrent cardiac events in patients with post-acute coronary syndrome. Biomarkers, 2020, 25, 235-240.	0.9	1
10	Circulating Biomarkers of Cell Adhesion Predict Clinical Outcome in Patients with Chronic Heart Failure. Journal of Clinical Medicine, 2020, 9, 195.	1.0	12
11	Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2099-2106.	1.4	13
12	Repeated Echocardiograms Do Not Provide Incremental Prognostic Value to Single Echocardiographic Assessment in Minimally Symptomatic Patients with Chronic Heart Failure: Results of the Bio-SHiFT Study. Journal of the American Society of Echocardiography, 2019, 32, 1000-1009.	1.2	7
13	Anti-Oxidized LDL Antibodies and Coronary Artery Disease: A Systematic Review. Antioxidants, 2019, 8, 484.	2.2	35
14	Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study. Thrombosis and Haemostasis, 2019, 119, 1947-1955.	1.8	14
15	Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission. American Heart Journal, 2019, 216, 143-146.	1.2	3
16	Details on high frequency blood collection, data analysis, available material and patient characteristics in BIOMArCS. Data in Brief, 2019, 27, 104750.	0.5	10
17	Reproducibility of the Pleth Variability Index in premature infants. Journal of Clinical Monitoring and Computing, 2018, 32, 457-464.	0.7	6
18	Dataset on blood biomarkers and GRACE score measured at admission for myocardial infarction in a large secondary hospital. Data in Brief. 2018. 21. 371-376.	0.5	2

#	Article	IF	CITATIONS
19	IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). EBioMedicine, 2018, 36, 63-72.	2.7	22
20	Addition of routinely measured blood biomarkers significantly improves GRACE risk stratification in patients with myocardial infarction. International Journal of Cardiology, 2018, 273, 237-242.	0.8	15
21	Mid-term outcomes of the Absorb BVS versus second-generation DES: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0197119.	1.1	13
22	Long-Term Follow-Up of the Randomized (BIOMArCS-2) Glucose Trial. Circulation, 2016, 134, 984-986.	1.6	2
23	Reproducibility of Microvascular Vessel Density Analysis in Sidestream Darkâ€Fieldâ€Derived Images of Healthy Term Newborns. Microcirculation, 2015, 22, 37-43.	1.0	18